Tag - Profound

Developments

Profound Medical gets FDA clearance to market TULSA-PRO for the treatment of prostate disease

Profound Medical (TSX:PRN; OTCQX:PRFMF) received FDA clearance to market TULSA-PRO for the ablation of prostate tissue, with an FDA label allowing U.S. surgeons to perform procedures on both malignant and benign tissue...

August 16, 2019

Executive Moves

Profound Medical names senior finance executive, Steve Forte, to board

Steve Forte Profound Medical (TSX:PRN; OTCQX:PRFMF) appointed seasoned cross-border finance leader, Steve Forte, as a director and member of the board’s audit committee. Most recently, Mr. Forte was CFO of Clementia...

August 15, 2019

Executive Moves

Profound Medical appoints Ian Heynen as SVP sales and marketing

Profound Medical (TSXV:PRN; OTCQX:PRFMF) appointed Ian Heynen as SVP of sales and marketing. Mr. Heynen brings to Profound more than 15 years of progressive leadership experience, working with medical device companies...

April 23, 2018

Tag - Profound

Profound Medical gets FDA clearance to market TULSA-PRO for the treatment of prostate disease

Profound Medical names senior finance executive, Steve Forte, to board

Profound Medical appoints Ian Heynen as SVP sales and marketing

General

More